Reason for request
New indication
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding.
|
Clinical Added Value
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
48D1ExfafyDsGaM7